Recent News

• 04.22.2025 - Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
• 04.03.2025 - Ernexa Therapeutics Closes New Funding Round
• 03.25.2025 - Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
• 02.26.2025 - Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Recent Filings

• 04.16.2025 - S-3 Registration statement under Securities Act of 1933
• 04.14.2025 - ARS Annual Report to Security Holders
• 04.14.2025 - DEF 14A Other definitive proxy statements
• 04.11.2025 - D Notice of Exempt Offering of Securities
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.04.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.03.2025 - PRE 14A Other preliminary proxy statements
• 04.03.2025 - 8-K Current report
• 03.26.2025 - 8-K Current report
• 03.24.2025 - 8-K Current report